Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Joy U, Okaa"'
Autor:
Rita O Oladele, Alexander M Jordan, Joy U Okaa, Iriagbonse I Osaigbovo, Shuwaram A Shettima, Nathan Y Shehu, Adeyinka A Davies, Yahaya Mohammed, Mary A Alex-Wele, Garba Iliyasu, Jude C Nwaokenye, Samuel A Fayemiwo, Ubong A Udoh, Titilola Gbajabiamila, David W Denning, Tom M Chiller
Publikováno v:
PLOS Global Public Health, Vol 3, Iss 1, p e0001313 (2023)
As of 2018, cryptococcal antigen (CrAg) screening in patients with advanced human immunodeficiency virus (HIV) disease (AHD) was not routinely implemented in Nigeria despite being recommended in the national HIV treatment guidelines. Our aim was to d
Externí odkaz:
https://doaj.org/article/f8df9a398cd54855b3f1bef741859557
Autor:
Rita O. Oladele, Akaninyene A. Otu, Oluwaseyi J. Balogun, Oladayo M. Babalola, Augustina O. Nwosu, Iriagbonse Iyabo Osaigbovo, Titilayo Gbajabiamila, Nicholas K. Irurhe, Samuel A. Fayemiwo, Shuwaram A. Shettima, Nkolika Stella Uwaezuoke, Chinagozi Precious Edwin, Toyese Stephen Ayanbeku, Joy U. Okaa, Charles John Elikwu, David W. Denning, Phyllis J. Kanki, Folasade T. Ogunsola
Publikováno v:
Therapeutic Advances in Infectious Disease, Vol 8 (2021)
Background and objectives: Commercial Aspergillus IgG antibody assays have become pivotal in the current diagnosis of chronic pulmonary aspergillosis (CPA). However, diagnostic cutoffs have been found to vary from manufactures’ recommendations in d
Externí odkaz:
https://doaj.org/article/486b8552a0944c63b161f53d030c2e6a
Autor:
Rita O, Oladele, Akaninyene A, Otu, Oluwaseyi J, Balogun, Oladayo M, Babalola, Augustina O, Nwosu, Iriagbonse, Iyabo Osaigbovo, Titilayo, Gbajabiamila, Nicholas K, Irurhe, Samuel A, Fayemiwo, Shuwaram A, Shettima, Nkolika Stella, Uwaezuoke, Chinagozi Precious, Edwin, Toyese Stephen, Ayanbeku, Joy U, Okaa, Charles John, Elikwu, David W, Denning, Phyllis J, Kanki, Folasade T, Ogunsola
Publikováno v:
Therapeutic Advances in Infectious Disease
Background and objectives: Commercial Aspergillus IgG antibody assays have become pivotal in the current diagnosis of chronic pulmonary aspergillosis (CPA). However, diagnostic cutoffs have been found to vary from manufactures’ recommendations in d
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::9f0e43ff3624b6d59e542d7c5d63e77d
https://pubmed.ncbi.nlm.nih.gov/34646555
https://pubmed.ncbi.nlm.nih.gov/34646555
Autor:
Rita O. Oladele, Titilayo Gbajabiamila, Samuel A. Fayemiwo, Folasade Ogunsola, Akaninyene Otu, Charles John Elikwu, Nkolika Stella Uwaezuoke, Iriagbonse Iyabo Osaigbovo, Toyese Stephen Ayanbeku, Oladayo M Babalola, Phyllis J. Kanki, David W. Denning, Augustina O. Nwosu, Chinagozi Precious Edwin, NK Irurhe, O.J. Balogun, Shuwaram A Shettima, Joy U Okaa
Publikováno v:
Therapeutic Advances in Infectious Disease. 8:204993612110501
Background and objectives: Commercial Aspergillus IgG antibody assays have become pivotal in the current diagnosis of chronic pulmonary aspergillosis (CPA). However, diagnostic cutoffs have been found to vary from manufactures’ recommendations in d
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d6bc87e6234074667234ef191847ea4c
https://doi.org/10.1177/20499361211050158
https://doi.org/10.1177/20499361211050158